This Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, and the Global Self-Care Federation (previously called the World Self-Medication Industry).
Read moreGeneva, 7 February, 2020: IFPMA welcomes the holistic approach of WHO to influenza preparedness, as well as the call for suggestions for further sensitizing Member States to the importance of timely influenza virus sharing, and for ways to promote influenza prevention and control strategies, including through the use of seasonal vaccination. We are concerned that...
Read moreGeneva, 7 February, 2020: IFPMA welcomes the addition of Neglected Tropical Diseases (NTDs) to the Executive Board agenda. The WHO’s development of the second roadmap on NTDs for 2021-2030 is timely, as we anticipate the coming to an end of the London Declaration – a coalition established in 2012, in which the biopharmaceutical industry pledged...
Read moreGeneva, 7 February, 2020: This statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, supported by the International Council of Biotechnology Associations. IFPMA and ICBA would like to thank the WHO secretariat for its efforts to monitor progress on the overall implementation of the GSPA-PHI. The innovative biotechnology and biopharmaceutical industries engaged...
Read moreGeneva, 6 February, 2020: IFPMA strongly supports WHO’s plan to address the global burden of cervical cancer. The 90-70-90 goals are ambitious for every country and different approaches and timeframes will be required across settings. We urge WHO to take a strong leadership role in galvanizing the substantial investments in health systems and infrastructure needed...
Read moreGeneva, 6 February, 2020: IFPMA welcomes a renewed immunization strategy, supporting Heads of States’ commitment to “accelerate efforts towards the achievement of UHC by 2030 to ensure healthy lives and promote well-being for all throughout the life-course”. IFPMA supports SAGE recommendations, in particular integration between disease-elimination initiatives and national immunization programs as achieved in “Defeating...
Read moreDelivered by David Gleicher (MSD) as part of the UHC 2030 Private Sector Constituency Geneva, 5 February, 2020: Universal Health Coverage means that all individuals and communities have access to quality essential health services without risk of financial hardship. The private sector is well-positioned to contribute to UHC efforts and already provides health products and...
Read moreDelivered by Vanessa Peberdy, Head of NCD Policy & Advocacy & WHO Engagement Geneva, 4 February 2020: This Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, the Global Self-Care Federation, supported by the International Council of Biotechnology Associations. We represent key...
Read moreGeneva, 31 January 2020: The research-based biopharmaceutical industry (IFPMA and its members) is deeply concerned by the coronavirus (2019-nCoV acute respiratory disease) epidemic. Outbreaks of novel virus infections for which there is no known effective antiviral therapy present a serious threat to public health. IFPMA and its members stand together in support with the global...
Read moreG-FINDER report: Investment in neglected disease R&D by multinational pharmaceutical companies grew by more than a quarter in 2018, reaching its highest-ever level Geneva, 30 January 2020: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 2019 G-FINDER report, which tracks public, private and philanthropic investment into product R&D for neglected diseases. The report shows...
Read moreAMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment. Alliance records US$6bn annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment...
Read moreGlobal Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative biopharmaceutical industry and more than 850 partners to support the SDGs. Users can explore collaborations by SDG target, disease area, program strategy, and more. Users are also encouraged to connect with partners via the platform to drive new collaborations in...
Read more